8-K: MiniMed Reports Record FY26 Sales, Strong Q4 Growth

MiniMed announced record fiscal year 2026 net sales exceeding $3 billion, with Q4 sales up 15.6% year-over-year, driven by international markets and new product clearances.

Summary

• MiniMed achieved record net sales of $3.102 billion for fiscal year 2026, a 14.2% increase as reported and 8.0% organically.
• Fourth quarter fiscal year 2026 net sales reached $837 million, up 15.6% as reported and 8.7% organically, with strong international performance.
• International net sales grew 22.4% as reported to $599 million in Q4, while U.S. net sales were $238 million, a 1.5% increase.
• Worldwide New Pumps Sold (NPS) increased 7.4% quarter-over-quarter to approximately 42,000 units in Q4.
• The worldwide CGM Attachment Rate increased to 68% in Q4, up 100 basis points sequentially.
• The company received FDA clearance for MiniMed FlexTM and CE Mark for Instinct, and launched MiniMed GoTM Smart MDI globally.
• MiniMed projects fiscal year 2027 organic revenue growth of approximately 10% and an Adjusted EBITDA margin of approximately 16%.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with record sales and strong growth, despite a reported net loss, due to strategic product advancements and a confident future outlook.

Positives

• Record annual net sales surpassing $3 billion for the first time, with 14.2% reported and 8.0% organic growth in FY26.
• Strong Q4 net sales growth of 15.6% reported and 8.7% organic, indicating continued business momentum.
• Significant international sales growth of 22.4% reported and 12.2% organic in Q4, highlighting global market penetration.
• Successful FDA clearance for MiniMed FlexTM and CE Mark for Instinct, enabling future product launches.
• Global launch of MiniMed GoTM Smart MDI system, expanding product offerings.
• Increase in worldwide CGM Attachment Rate to 68% in Q4, up 100 bps sequentially, showing increased adoption of continuous glucose monitoring.
• Extension of partnership with Abbott for dual glucose-ketone sensors, enhancing integrated diabetes management solutions.

Negatives

• Worldwide New Pumps Sold were unchanged year-over-year at approximately 145,000 units for the full fiscal year 2026.
• U.S. net sales growth was modest at 1.5% reported and organic for both Q4 and the full fiscal year 2026.
• The company reported a net loss of $315 million for the full fiscal year 2026 and $183 million for the fourth quarter.
• Operating expenses, including R&D and SG&A, increased year-over-year, contributing to the net loss.

Risks

• Risks related to competitive factors in the diabetes technology market.
• Difficulties and delays inherent in the development, manufacturing, marketing, and sale of medical products.
• Government regulation impacting product approvals and market access.
• Geopolitical conflicts and changing global trade policies that could affect operations and supply chains.
• General economic conditions that may impact consumer spending and healthcare budgets.

Future Outlook

For fiscal year 2027, MiniMed expects organic revenue growth of approximately 10%, including a 1.0-1.5% benefit from an extra week in the fiscal year. The company also anticipates an Adjusted EBITDA margin of approximately 16%.

Management Comments

• MiniMed delivered a strong finish to our fiscal year, driven by strength in international markets and continued global adoption of the MiniMedTM 780G system.
• Looking ahead, we're confident that our launches of MiniMed FlexTM and MiniMed GoTM will support long-term growth acceleration and value creation.

Industry Context

StockSavvy.ai notes that MiniMed's strong performance, particularly in international markets and with the adoption of its integrated diabetes management systems, aligns with broader industry trends towards connected devices and advanced therapeutic solutions. The company's focus on new product clearances and launches positions it to capitalize on the growing demand for innovative diabetes care.

Comparison to Industry Standards

• MiniMed's reported organic revenue growth of 8.0% for FY26 is robust compared to the broader medical device industry average, which has seen varied performance depending on sub-sector and geographic region.
• The company's international sales growth of 11.2% organically in FY26 outpaces many competitors in developed markets, suggesting strong execution in key overseas territories.
• The increase in CGM attachment rate to 68% indicates a higher level of integration and data utilization than many competitors, reflecting a more advanced ecosystem.
• While MiniMed reported a net loss, this is not uncommon for companies investing heavily in R&D and product launches within the competitive diabetes technology sector, where companies like Dexcom and Tandem Diabetes Care also show significant R&D expenditures.

Legal Proceedings

• Certain litigation charges were recorded in operating expenses.

Stakeholder Impact

• Shareholders: Potential for increased value driven by record sales, product innovation, and positive future outlook, though offset by current net losses.
• Customers: Access to new and advanced diabetes management technologies like MiniMed FlexTM and MiniMed GoTM, potentially improving diabetes management.
• Employees: Continued investment in R&D and global expansion may lead to job growth and opportunities within the company.
• Partners (e.g., Abbott): Strengthened collaboration with the extension of the dual glucose-ketone sensor partnership.

Next Steps

• Launch of MiniMed FlexTM insulin pump in the U.S. this month (June 2026).
• Global launch of MiniMed GoTM Smart MDI system.
• Launch of MiniMed 780G with Instinct sensor in Europe later this month (June 2026).
• Commencement of U.S. pivotal study for ViveraTM third generation fully closed loop algorithm.
• Continued commercialization of MiniMedTM 780G system with Simplera and Instinct sensors.

Key Dates

Recommendation

The company demonstrates strong revenue growth and strategic product advancements, positioning it well for the future. However, the persistent net losses and the need for continued investment in R&D and market expansion warrant a cautious 'hold' rating until profitability trends improve and the impact of new product launches is fully realized.

Keywords

MiniMed, Diabetes Technology, Insulin Pump, CGM, Earnings Release, Financial Results, FDA Clearance, CE Mark